All News GC Biopharma Corp.

Equities

A006280

KR7006280002

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-09 EDT			5-day change	1st Jan Change
114,600 ^KRW	+0.44%		-0.95%	-8.69%

05-03	Green Cross Widens Q1 Loss, Sales Inch Up 2%	MT
03-20	GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Green Cross Widens Q1 Loss, Sales Inch Up 2%	05-03	MT
GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Ex-dividend day for final dividend	12-26	FA
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	12-17	CI
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea	12-01	CI
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
GC Biopharma Applies for MFDS Approval	11-05	CI
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases	23-10-12	CI
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Green Cross's Net Income Plunges in Q2	23-08-02	MT
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt	23-07-21	CI
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent	23-07-18	PU
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia	23-06-01	CI
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Green Cross Swings to Loss in Q1	23-05-02	MT
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	23-03-01	MT
GC Biopharma Receives WHO Pre-Qualification for BARYCELA	23-02-19	CI
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea	23-02-08	CI
Ex-dividend day for final dividend	22-12-27	FA
Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors	22-11-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News GC Biopharma Corp.

Equities

A006280

KR7006280002

All News

Filters